Woodford Investment Management Ltd

Person Signing this Report on Behalf of Reporting Manager:

This amendment is being filed to add an additional issuer (NuCana plc) and to reflect the following: With respect to Evofem Biosciences, Inc. ("Evofem"), the Reporting Manager, acting as agent for and on behalf of the funds it manages who own shares of Evofem common stock, par value $0.0001 per share ("Evofem Stock") (the "Funds"), has entered into a voting agreement with Evofem, obligating the Reporting Manager to cause each Fund to deliver to Evofem a duly executed irrevocable proxy. Each Fund, including LF Woodford Equity Income Fund and Woodford Patient Capital Trust, who are Other Included Managers whose holdings are separately included on the Information Table, has executed and delivered such proxy to Evofem. The proxy appoints any designee of Evofem as the sole and exclusive attorney and proxy of the Fund to represent the Fund and to vote at every meeting of the stockholders of Evofem (including any actions by written consent) with respect to all the shares of Evofem Stock owned by the Fund in excess of 19.5% of the then outstanding shares of Evofem Stock in the same proportion as the shares voted by all other stockholders (excluding the Fund) voting on or consenting to such matters. Accordingly, each Fund (as record holder of the shares) only has voting power with respect to the shares it beneficially owns up to and including that 19.5% threshold ("Threshold Shares"); the Reporting Manager shares voting power with respect to such Threshold Shares. Voting authority with respect to the Evofem Stock over which neither the Reporting Manager nor the Funds has voting power (because such 19.5% threshold has been exceeded) is reported as "none" in Column 8 of the Information Table. For purposes of this calculation, the total outstanding Evofem shares used was 17,763,340 shares of Evofem Stock outstanding as of February 9, 2018, as reported in Evofem's Annual Report on Form 10-K, filed with the SEC on February 26, 2018. Please refer to the Form of Voting Agreement, which is incorporated by reference to Exhibit 4.10 of Evofem's Registration Statement on Form S-4 (No. 333-221592) filed on November 15, 2017 and the Reporting Manager's Schedule 13G with respect to the Evofem Stock filed by the Reporting Manager on June 11, 2018, for more information.

Other Included Managers (5):